Raymond James Financial
FDMT icon

Raymond James Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Raymond James Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Sell
266,147
-211,358
-44% -$1.84M ﹤0.01% 3182
2025
Q4 		$3.58M Buy
477,505
+6,235
+1% +$63.2K ﹤0.01% 2786
2025
Q3 		$4.1M Buy
471,270
+15,800
+3% +$94.4K ﹤0.01% 2609
2025
Q2 		$1.69M Buy
455,470
+161,091
+55% +$566K ﹤0.01% 3217
2025
Q1 		$951K Buy
294,379
+181,475
+161% +$855K ﹤0.01% 3530
2024
Q4 		$629K Buy
+112,904
New +$886K ﹤0.01% 3763

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Raymond James Financial's FDMT Position: Q1 2026 in Review

Raymond James Financial reduced its 4D Molecular Therapeutics (FDMT) stake by 44% in Q1 2026, selling an estimated $1.84M and leaving 266,147 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3182.

Raymond James Financial first reported a position in FDMT in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.1M in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Raymond James Financial held 266,147 shares of 4D Molecular Therapeutics worth $2.48M as of Q1 2026.
  • Raymond James Financial sold 211,358 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.84M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3182 holding.
  • Raymond James Financial first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's 4D Molecular Therapeutics position peaked at $4.1M in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.